Biosimilars for Breast Cancer May Provide More Treatment Options

Susan G. Komen Austin

Biosimilar pharmalogics are made from living organisms and offer a new and exciting way to treat breast cancer which can be less expensive, have fewer side effects and replicate the results of their chemical based counterparts.Dr. Chen earned her medical degree from the Perelman School of Medicine of the University of Pennsylvania and her Master’s of Public Health from the Harvard T.H. Chan School of Public Health. She is a breast cancer medical oncologist and cancer epidemiologist. She works with the Nurses’ Health Study and has published extensively on nutritional, lifestyle, and hormonal factors that influence breast cancer risk and survival. She also has a particular interest in translating epidemiologic findings to breast cancer clinical practice. She is currently the study chair for the Aspirin for Breast Cancer (ABC) Trial, a large randomized trial of aspirin vs placebo to prevent breast cancer recurrence run through the Alliance of Clinical Trials in Oncology in the United States. Thank you to our partners who made this podcast possible - Merk and Amgen Oncology.